Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study)

Antiviral Therapy

Volumn 6, Issue 4, 2001, Pages 255-262

  Florence, Eric ^a   Dreezen, Christa ^a   Desmet, Patrick ^a   Smets, Eric ^a   Fransen, Katrien ^a   Vandercam, Bernard ^a   Pelgrom, Jolanda ^a   Clumeck, Nathan ^a   Colebunders, Robert ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; LIPID; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NEPHROLITHIASIS; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SAQUINAVIR; VIRAL LOAD;

EID: 0035715067     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects
3. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
4. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents
5. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection
6. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism
7. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
8. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
9. Dual protease inhibitor therapv in HIV-infected patients: Pharmacologic rationale and clinical benefits
10. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: Theory and practice
11. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
12. Indinavir: A review of its use in the management of HIV infection
13. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
14. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
15. The Danish protease inhibitor study: A randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection
16. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial
17. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy
18. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs
19. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
20. The effect of treatment intensification in HIV-infection: A study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
21. Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study
22. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients
23. Statistical issues
24. Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment